Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy
Status:
Completed
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
The study is an open-label phase 2 clinical and translational trial designed to evaluate the
effects of nilotinib on the leukemic stem cell population in subjects with newly diagnosed
chronic phase chronic myeloid leukemia (Ph+ CML in CP). Nilotinib is FDA-approved to treat
subjects with Ph+ CML in CP. Subjects on study will be monitored according to accepted
National Cancer Comprehensive Network [NCCN] clinical guidelines for 24 months. After 24
months, if continued therapy is needed subjects will be transitioned to commercial supply of
study drug.